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REGRESSION AND PREVENTION OF LEFT VENTRICULAR HYPERTROPHY 
ARE POSSIBLE IN HYPERTENSIVE HEART TRANSPLANT RECIPIENTS 
Christoph Spes MO, Stefan 21i- 
ie MD, Bernhard Kemkes MD. Karl 
.Ul.Innenstadt, University of Munich, FRG 
Arterial hypertension develops in most heart transplant 
recipients (HTXP) on cyclosporine. Th 
investigates 1) whether in HTXP with 
s prospective study 
V hypertrophy(H)re- 
gression can be induced by antihypertensive therapy (T) 
and 2) whether T can prevent LVH when started early after 
onset of hypertension. 39 HTXP were evaluated with echo- 
cardiogjraphy and 24h-blood-pressure(BP)-monitoring before 
and 1.5, 3, 6, 9 and 12 months(m) after introduction of T 
(e,$alapril IO-20mg/d + furosemide 20-80mg/d +(in 26 HTXP) 
verapamil 120-360mg/d). Group I (diast. septa;(VS)+pos- 
terior wall(PW) >23mm)included 17 HTXP (14m,3f, 43+10yrs, 
18+15months pop); group II (VS+PW<23mm) 22 HTXP (TOm,2f, 
46Tgyrs,7+6months pop).Changes in mean BP(mmHg) over 24h, 
LV-mass(grderived from 2D echo with a cylinder-hemiellip- 
soid formula) and parameters of LV function were compared 
in both groups (x$D, **/*:p~0.01/0.001 vs pre T values): 
mean BP11 lZOT9 99T8* 98T77* 97Q* 9777" 95%" 
vs+pw I 26T2 2472** 23T2* 22T2" 2Gl** 2172" 
vs+pw II 2G-l 2oT-l 2OTl 2OTl 20q** 20=q** 
LV mass I 219T27 21OT'l4** 188T27* 18O‘if25*18OT25* 171Tl9* 
LV mass11 188T28 184T29 177727 176y26 168’c24* 170723* 
Heart rate, LTf volum%, SV, EF and CO-did noT differ-bet- 
ween nrouo I and II and did not change during follow uo. 
Concluiion: Though the initial extentdof hypekension and 
the antihypertensive effect of T were comparable and LV 
size and function the same in both groups, VS+PW ard LV 
mass decreased signif. more (p 0.01) in group I. Thus, in 
HTXP with LVH rapid regression was induced by T, while in 
HTXP with normal LV mass development of LVH was prevented. 
